secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2026-07-24T20:01:26+00:00
Accession:  0001193125-26-316041
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind gets FDA approval for Furoscix ReadyFlow; raises $50M in private placement
--------------------------------------------------------------------------------

- FDA approved Furoscix ReadyFlow (furosemide injection) for edema in adults with heart failure or chronic kidney disease.
- Private placement of 10,440,838 shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, led by Frazier Life Sciences.
- Gross proceeds ~$50M; net proceeds to fund $45M CVR payment triggered by FDA approval and for general corporate purposes.
- Pre-funded warrants have $0.01 exercise price, no expiration, subject to 19.99% beneficial ownership limitation.
- Company agreed to file resale registration statement within 30 days of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/0001193125-26-316041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/d63182d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer